Rotational atherectomy: Difference between revisions
Jump to navigation
Jump to search
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
[[Image:Rotablator.jpg|right|thumb|Rotablator bur]] | [[Image:Rotablator.jpg|right|thumb|Rotablator bur]] | ||
| Line 5: | Line 6: | ||
==Overview== | ==Overview== | ||
Rotablation is used as a debulking device. It is generally not used as a stand alone device, and is generally used to facilitate greater lumen expansion via improving vessel compliance prior to stent placement. The procedure can be done in coronary arteries and in peripheral arteries. | [[Rotablation]] is used as a debulking device. It is generally not used as a stand alone device, and is generally used to facilitate greater lumen expansion via improving vessel compliance prior to stent placement. The procedure can be done in coronary arteries and in peripheral arteries. | ||
==Coronary rotational atherectomy== | ==Coronary rotational atherectomy== | ||
The device used in the coronary artery is called the Rotablator® Device. There are other devices as part of the system including the Rotablator® RotaLink® Advancer, RotaLink® Catheters, the RotaLink® Plus Pre-Connected Exchangeable System, RotaWire® Guide Wires and Rotaglide™ System Lubricant. <ref> http:// | The device used in the coronary artery is called the Rotablator® Device. There are other devices as part of the system including the Rotablator® RotaLink® Advancer, RotaLink® Catheters, the RotaLink® Plus Pre-Connected Exchangeable System, RotaWire® Guide Wires and Rotaglide™ System Lubricant. | ||
==Indications== | |||
===Coronary Atherectomy=== | |||
<ref name="pmid22070837">{{cite journal |author=Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH |title=2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions |journal=[[Journal of the American College of Cardiology]] |volume=58 |issue=24 |pages=2550–83 |year=2011 |month=December|pmid=22070837|doi=10.1016/j.jacc.2011.08.006|url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(11)02875-0|accessdate=2011-12-08|url=http://content.onlinejacc.org/cgi/reprint/58/24/2550.pdf|PDF}}</ref> | |||
== | {|class="wikitable" | ||
# The target lesion is in a native vessel, not a saphenous vein graft | |- | ||
# The target lesion is deemed to be undilatable by a balloon due to calcium or fibrosis. | |colspan="1" style="text-align:center; background:LightCoral"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (No Benefit) | ||
# The target lesion is an ostial lesion | |||
# The target lesion is located at a bifurcation and debulking is required to reduced the risk of plaque shift | |- | ||
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' [[Rotational atherectomy]] should not be performed routinely for de-novo lesions or [[stent|in-stent]] [[restenosis]]. <ref name="pmid15028347">{{cite journal |author=Bittl JA, Chew DP, Topol EJ, Kong DF, Califf RM |title=Meta-analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty |journal=[[Journal of the American College of Cardiology]] |volume=43 |issue=6|pages=936–42 |year=2004 |month=March |pmid=15028347 |doi=10.1016/j.jacc.2003.10.039|url=http://linkinghub.elsevier.com/retrieve/pii/S0735109704000142|accessdate=2011-12-10}}</ref><ref name="pmid12766743">{{cite journal |author=Mauri L, Reisman M, Buchbinder M, Popma JJ, Sharma SK, Cutlip DE, Ho KK, Prpic R, Zimetbaum PJ, Kuntz RE|title=Comparison of rotational atherectomy with conventional balloon angioplasty in the prevention of restenosis of small coronary arteries: results of the Dilatation vs Ablation Revascularization Trial Targeting Restenosis (DART) |journal=[[American Heart Journal]] |volume=145 |issue=5|pages=847–54 |year=2003 |month=May |pmid=12766743 |doi=10.1016/S0002-8703(03)00080-2|url=http://linkinghub.elsevier.com/retrieve/pii/S0002870303000802|accessdate=2011-12-10}}</ref><ref name="pmid9236422">{{cite journal |author=Reifart N, Vandormael M, Krajcar M, Göhring S, Preusler W, Schwarz F, Störger H, Hofmann M, Klöpper J, Müller S, Haase J|title=Randomized comparison of angioplasty of complex coronary lesions at a single center. Excimer Laser, Rotational Atherectomy, and Balloon Angioplasty Comparison (ERBAC) Study|journal=[[Circulation]] |volume=96 |issue=1 |pages=91–8 |year=1997 |month=July |pmid=9236422 |doi=|url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=9236422|accessdate=2011-12-10}}</ref><ref name="pmid11827923">{{cite journal |author=vom Dahl J, Dietz U, Haager PK, Silber S, Niccoli L, Buettner HJ, Schiele F, Thomas M, Commeau P, Ramsdale DR, Garcia E, Hamm CW, Hoffmann R, Reineke T, Klues HG |title=Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the angioplasty versus rotational atherectomy for treatment of diffuse in-stent restenosis trial (ARTIST) |journal=[[Circulation]] |volume=105 |issue=5|pages=583–8 |year=2002 |month=February |pmid=11827923 |doi=|url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=11827923|accessdate=2011-12-10}}</ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki> | |||
|} | |||
{|class="wikitable" | |||
|- | |||
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | |||
|- | |||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' [[Rotational atherectomy]] is reasonable for fibrotic or [[dystrophic calcification|heavily calcified]] lesions that might not be crossed by a [[balloon catheter]] or adequately dilated before [[stent|stent implantation]]. <ref name="pmid9236427">{{cite journal |author=Moussa I, Di Mario C, Moses J, Reimers B, Di Francesco L, Martini G, Tobis J, Colombo A |title=Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results|journal=[[Circulation]] |volume=96 |issue=1 |pages=128–36 |year=1997 |month=July |pmid=9236427|doi= |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=9236427|accessdate=2011-12-10}}</ref><ref name="pmid20636844">{{cite journal |author=Vaquerizo B, Serra A, Miranda F, Triano JL, Sierra G, Delgado G, Puentes A, Mojal S, Brugera J |title=Aggressive plaque modification with rotational atherectomy and/or cutting balloon before drug-eluting stent implantation for the treatment of calcified coronary lesions |journal=[[Journal of Interventional Cardiology]] |volume=23 |issue=3 |pages=240–8 |year=2010 |month=June |pmid=20636844|doi=10.1111/j.1540-8183.2010.00547.x |url=http://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0896-4327&date=2010&volume=23&issue=3&spage=240|accessdate=2011-12-10}}</ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | |||
|} | |||
# The target lesion is in a native vessel, not a [[saphenous vein]] graft | |||
# The target lesion is deemed to be undilatable by a balloon due to calcium or [[fibrosis]]. | |||
# The target lesion is an [[ostial]] lesion | |||
# The target lesion is located at a [[bifurcation]] and debulking is required to reduced the risk of [[plaque]] shift | |||
# The target lesion could not be crossed with the primary device | # The target lesion could not be crossed with the primary device | ||
| Line 20: | Line 39: | ||
The following are contraindications to the performance of coronary rotational atherectomy <ref>http://www.bostonscientific.com/Device.bsci?page=ResourceDetail&navRelId=1000.1003&method=DevDetailHCP&id=10081831&resource_type_category_id=1&resource_type_id=91&pageDisclaimer=Disclaimer.ProductPage</ref> | The following are contraindications to the performance of coronary rotational atherectomy <ref>http://www.bostonscientific.com/Device.bsci?page=ResourceDetail&navRelId=1000.1003&method=DevDetailHCP&id=10081831&resource_type_category_id=1&resource_type_id=91&pageDisclaimer=Disclaimer.ProductPage</ref> | ||
# Ejection fraction < 30% | # [[Ejection fraction]] < 30% | ||
# Shock or hypotension | # Shock or [[hypotension]] | ||
# The target lesion is the sole remaining conduit | # The target lesion is the sole remaining conduit | ||
# The presence of dissection. The patient should be managed conservatively for approximately four weeks to permit the dissection to heal before treating the lesion with the Rotablator system. | # The presence of [[dissection]]. The patient should be managed conservatively for approximately four weeks to permit the dissection to heal before treating the lesion with the Rotablator system. | ||
# Severe angulation at the target lesion | # Severe angulation at the target lesion | ||
# An occlusions through which a guide wire will not pass | # An occlusions through which a [[guide wire]] will not pass | ||
# The lesion is in a saphenous vein graft | # The lesion is in a saphenous vein graft | ||
# Angiographic evidence of thrombus | # Angiographic evidence of [[thrombus]] | ||
==Strategies to reduce no reflow during the procedure== | ==Strategies to reduce no reflow during the procedure== | ||
| Line 35: | Line 54: | ||
# Minimal deceleration during the bur runs | # Minimal deceleration during the bur runs | ||
# Allowing a period of recovery between bur runs | # Allowing a period of recovery between bur runs | ||
# Avoid over-sizing the bur to minimize downstream embolization | # Avoid over-sizing the bur to minimize downstream [[embolization]] | ||
# Use of a "Rotablator flush": | # Use of a "Rotablator flush": | ||
:*0.9% NS 1000 cc | :*0.9% NS 1000 cc | ||
:*10,000 Units of unfractionated heparin (10 units / ml) | :*10,000 Units of [[unfractionated heparin]] (10 units / ml) | ||
:*Verapamil 10 mg (10 micrograms / ml) | :*[[Verapamil]] 10 mg (10 micrograms / ml) | ||
:*Nitroglycerin 5 mg (5 microgams / ml) | :*[[Nitroglycerin]] 5 mg (5 microgams / ml) | ||
==Efficacy== | ==Efficacy== | ||
| Line 46: | Line 65: | ||
===The ERBAC Trial=== | ===The ERBAC Trial=== | ||
ERBAC was a single center trial in which patients with complex lesion were randomized to either balloon angioplasty (n=222), excimer laser angioplasty (n=232), or rotational atherectomy (n=231). <ref name="pmid9236422">{{cite journal |author=Reifart N, Vandormael M, Krajcar M, ''et al'' |title=Randomized comparison of angioplasty of complex coronary lesions at a single center. Excimer Laser, Rotational Atherectomy, and Balloon Angioplasty Comparison (ERBAC) Study |journal=Circulation |volume=96 |issue=1 |pages=91–8 |year=1997 |month=July |pmid=9236422 |doi= |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=9236422}}</ref> The primary end point (procedural success defined as diameter stenosis <50%, absence of death, Q-wave myocardial infarction, or coronary artery bypass surgery) was higher among rotablation (89%) versus laser (77%) versus balloon angioplasty patients (80%, P=.0019). There was no difference in major in-hospital complications (3.2% versus 4.3% versus 3.1%, P=.71). Despite improved acute procedural outcomes, 6-month target lesion revascularization was more frequent in the rotational atherectomy group (42.4%) and the excimer laser group (46.0%) versus the angioplasty group (31.9%, P=.013). <ref name="pmid9236422">{{cite journal |author=Reifart N, Vandormael M, Krajcar M, ''et al'' |title=Randomized comparison of angioplasty of complex coronary lesions at a single center. Excimer Laser, Rotational Atherectomy, and Balloon Angioplasty Comparison (ERBAC) Study |journal=Circulation |volume=96 |issue=1 |pages=91–8 |year=1997 |month=July |pmid=9236422 |doi= |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=9236422}}</ref> | ERBAC was a single center trial in which patients with complex lesion were randomized to either [[balloon angioplasty]] (n=222), [[excimer]] [[laser angioplasty]] (n=232), or rotational atherectomy (n=231). <ref name="pmid9236422">{{cite journal |author=Reifart N, Vandormael M, Krajcar M, ''et al'' |title=Randomized comparison of angioplasty of complex coronary lesions at a single center. Excimer Laser, Rotational Atherectomy, and Balloon Angioplasty Comparison (ERBAC) Study |journal=Circulation |volume=96 |issue=1 |pages=91–8 |year=1997 |month=July |pmid=9236422 |doi= |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=9236422}}</ref> The primary end point (procedural success defined as diameter [[stenosis]] <50%, absence of death, Q-wave myocardial infarction, or [[coronary artery bypass surgery]]) was higher among rotablation (89%) versus laser (77%) versus balloon angioplasty patients (80%, P=.0019). There was no difference in major in-hospital complications (3.2% versus 4.3% versus 3.1%, P=.71). Despite improved acute procedural outcomes, 6-month target lesion revascularization was more frequent in the rotational atherectomy group (42.4%) and the excimer laser group (46.0%) versus the angioplasty group (31.9%, P=.013). <ref name="pmid9236422">{{cite journal |author=Reifart N, Vandormael M, Krajcar M, ''et al'' |title=Randomized comparison of angioplasty of complex coronary lesions at a single center. Excimer Laser, Rotational Atherectomy, and Balloon Angioplasty Comparison (ERBAC) Study |journal=Circulation |volume=96 |issue=1 |pages=91–8 |year=1997 |month=July |pmid=9236422 |doi= |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=9236422}}</ref> | ||
===The SPORT Trial=== | ===The SPORT Trial=== | ||
| Line 54: | Line 73: | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 19:33, 9 October 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Rotablation is used as a debulking device. It is generally not used as a stand alone device, and is generally used to facilitate greater lumen expansion via improving vessel compliance prior to stent placement. The procedure can be done in coronary arteries and in peripheral arteries.
Coronary rotational atherectomy
The device used in the coronary artery is called the Rotablator® Device. There are other devices as part of the system including the Rotablator® RotaLink® Advancer, RotaLink® Catheters, the RotaLink® Plus Pre-Connected Exchangeable System, RotaWire® Guide Wires and Rotaglide™ System Lubricant.
Indications
Coronary Atherectomy
| Class III (No Benefit) |
| "1. Rotational atherectomy should not be performed routinely for de-novo lesions or in-stent restenosis. [2][3][4][5] (Level of Evidence: A)" |
| Class IIa |
| "1. Rotational atherectomy is reasonable for fibrotic or heavily calcified lesions that might not be crossed by a balloon catheter or adequately dilated before stent implantation. [6][7] (Level of Evidence: C)" |
- The target lesion is in a native vessel, not a saphenous vein graft
- The target lesion is deemed to be undilatable by a balloon due to calcium or fibrosis.
- The target lesion is an ostial lesion
- The target lesion is located at a bifurcation and debulking is required to reduced the risk of plaque shift
- The target lesion could not be crossed with the primary device
Contraindications
The following are contraindications to the performance of coronary rotational atherectomy [8]
- Ejection fraction < 30%
- Shock or hypotension
- The target lesion is the sole remaining conduit
- The presence of dissection. The patient should be managed conservatively for approximately four weeks to permit the dissection to heal before treating the lesion with the Rotablator system.
- Severe angulation at the target lesion
- An occlusions through which a guide wire will not pass
- The lesion is in a saphenous vein graft
- Angiographic evidence of thrombus
Strategies to reduce no reflow during the procedure
- Liberal administration of calcium channel blockers such as diltiazem (200 micrograms administered via the intracoronary route)
- Multiple short runs of rotablation
- A slower initial speed of rotablation such as 140,000 to 160,000 rotations per minute (RPM)
- Minimal deceleration during the bur runs
- Allowing a period of recovery between bur runs
- Avoid over-sizing the bur to minimize downstream embolization
- Use of a "Rotablator flush":
- 0.9% NS 1000 cc
- 10,000 Units of unfractionated heparin (10 units / ml)
- Verapamil 10 mg (10 micrograms / ml)
- Nitroglycerin 5 mg (5 microgams / ml)
Efficacy
The comparative efficacy of rotational atherectomy has been compared in the following studies / trials:
The ERBAC Trial
ERBAC was a single center trial in which patients with complex lesion were randomized to either balloon angioplasty (n=222), excimer laser angioplasty (n=232), or rotational atherectomy (n=231). [4] The primary end point (procedural success defined as diameter stenosis <50%, absence of death, Q-wave myocardial infarction, or coronary artery bypass surgery) was higher among rotablation (89%) versus laser (77%) versus balloon angioplasty patients (80%, P=.0019). There was no difference in major in-hospital complications (3.2% versus 4.3% versus 3.1%, P=.71). Despite improved acute procedural outcomes, 6-month target lesion revascularization was more frequent in the rotational atherectomy group (42.4%) and the excimer laser group (46.0%) versus the angioplasty group (31.9%, P=.013). [4]
The SPORT Trial
This trial Randomized 735 patients to bare metal stenting with or without prior rotational atherectomy. There were better acute procedural results among patients pre-treated with rotational atherectomy. There was no difference in TLR rates in follow-up [9]
References
- ↑ Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH (2011). "2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions" (PDF). Journal of the American College of Cardiology. 58 (24): 2550–83. doi:10.1016/j.jacc.2011.08.006. PMID 22070837. Retrieved 2011-12-08. Text "PDF" ignored (help); Unknown parameter
|month=ignored (help) - ↑ Bittl JA, Chew DP, Topol EJ, Kong DF, Califf RM (2004). "Meta-analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty". Journal of the American College of Cardiology. 43 (6): 936–42. doi:10.1016/j.jacc.2003.10.039. PMID 15028347. Retrieved 2011-12-10. Unknown parameter
|month=ignored (help) - ↑ Mauri L, Reisman M, Buchbinder M, Popma JJ, Sharma SK, Cutlip DE, Ho KK, Prpic R, Zimetbaum PJ, Kuntz RE (2003). "Comparison of rotational atherectomy with conventional balloon angioplasty in the prevention of restenosis of small coronary arteries: results of the Dilatation vs Ablation Revascularization Trial Targeting Restenosis (DART)". American Heart Journal. 145 (5): 847–54. doi:10.1016/S0002-8703(03)00080-2. PMID 12766743. Retrieved 2011-12-10. Unknown parameter
|month=ignored (help) - ↑ 4.0 4.1 4.2 Reifart N, Vandormael M, Krajcar M, Göhring S, Preusler W, Schwarz F, Störger H, Hofmann M, Klöpper J, Müller S, Haase J (1997). "Randomized comparison of angioplasty of complex coronary lesions at a single center. Excimer Laser, Rotational Atherectomy, and Balloon Angioplasty Comparison (ERBAC) Study". Circulation. 96 (1): 91–8. PMID 9236422. Retrieved 2011-12-10. Unknown parameter
|month=ignored (help) - ↑ vom Dahl J, Dietz U, Haager PK, Silber S, Niccoli L, Buettner HJ, Schiele F, Thomas M, Commeau P, Ramsdale DR, Garcia E, Hamm CW, Hoffmann R, Reineke T, Klues HG (2002). "Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the angioplasty versus rotational atherectomy for treatment of diffuse in-stent restenosis trial (ARTIST)". Circulation. 105 (5): 583–8. PMID 11827923. Retrieved 2011-12-10. Unknown parameter
|month=ignored (help) - ↑ Moussa I, Di Mario C, Moses J, Reimers B, Di Francesco L, Martini G, Tobis J, Colombo A (1997). "Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results". Circulation. 96 (1): 128–36. PMID 9236427. Retrieved 2011-12-10. Unknown parameter
|month=ignored (help) - ↑ Vaquerizo B, Serra A, Miranda F, Triano JL, Sierra G, Delgado G, Puentes A, Mojal S, Brugera J (2010). "Aggressive plaque modification with rotational atherectomy and/or cutting balloon before drug-eluting stent implantation for the treatment of calcified coronary lesions". Journal of Interventional Cardiology. 23 (3): 240–8. doi:10.1111/j.1540-8183.2010.00547.x. PMID 20636844. Retrieved 2011-12-10. Unknown parameter
|month=ignored (help) - ↑ http://www.bostonscientific.com/Device.bsci?page=ResourceDetail&navRelId=1000.1003&method=DevDetailHCP&id=10081831&resource_type_category_id=1&resource_type_id=91&pageDisclaimer=Disclaimer.ProductPage
- ↑ Buchbinder M, et al. Circ 2000:II-663